TY - JOUR
T1 - Tissue proteome signatures associated with five grades of prostate cancer and benign prostatic hyperplasia
AU - Kawahara, Rebeca
AU - Recuero, Saulo
AU - Nogueira, Fabio C. S.
AU - Domont, Gilberto B.
AU - Leite, Katia R. M.
AU - Srougi, Miguel
AU - Thaysen-Andersen, Morten
AU - Palmisano, Giuseppe
PY - 2019/11
Y1 - 2019/11
N2 - The histology-based Gleason score (GS) of prostate cancer (PCa) tissue biopsy is the most accurate predictor of disease aggressiveness and an important measure to guide treatment strategies and patient management. The variability associated with PCa tumor sampling and the subjective determination of the GS are challenges that limit accurate diagnostication and prognostication. Thus, novel molecular signatures are needed to distinguish between indolent and aggressive forms of PCa for better patient management and outcomes. Herein, label-free LC-MS/MS proteomics is used to profile the proteome of 50 PCa tissues spanning five grade groups (n = 10 per group) relative to tissues from individuals with benign prostatic hyperplasia (BPH). Over 2000 proteins are identified albeit at different levels between and within the patient groups, revealing biological processes associated with specific grades. A panel of 11 prostate-derived proteins including IGKV3D-20, RNASET2, TACC2, ANXA7, LMOD1, PRCP, GYG1, NDUFV1, H1FX, APOBEC3C, and CTSZ display the potential to stratify patients from low and high PCa grade groups. Parallel reaction monitoring of the same sample cohort validate the differential expression of LMOD1, GYG1, IGKV3D-20, and RNASET2. The four proteins associated with low and high PCa grades reported here warrant further exploration as candidate biomarkers for PCa aggressiveness.
AB - The histology-based Gleason score (GS) of prostate cancer (PCa) tissue biopsy is the most accurate predictor of disease aggressiveness and an important measure to guide treatment strategies and patient management. The variability associated with PCa tumor sampling and the subjective determination of the GS are challenges that limit accurate diagnostication and prognostication. Thus, novel molecular signatures are needed to distinguish between indolent and aggressive forms of PCa for better patient management and outcomes. Herein, label-free LC-MS/MS proteomics is used to profile the proteome of 50 PCa tissues spanning five grade groups (n = 10 per group) relative to tissues from individuals with benign prostatic hyperplasia (BPH). Over 2000 proteins are identified albeit at different levels between and within the patient groups, revealing biological processes associated with specific grades. A panel of 11 prostate-derived proteins including IGKV3D-20, RNASET2, TACC2, ANXA7, LMOD1, PRCP, GYG1, NDUFV1, H1FX, APOBEC3C, and CTSZ display the potential to stratify patients from low and high PCa grade groups. Parallel reaction monitoring of the same sample cohort validate the differential expression of LMOD1, GYG1, IGKV3D-20, and RNASET2. The four proteins associated with low and high PCa grades reported here warrant further exploration as candidate biomarkers for PCa aggressiveness.
KW - biomarkers
KW - gleason score
KW - mass spectrometry
KW - prostate cancer
KW - proteome
KW - proteomics
UR - http://www.scopus.com/inward/record.url?scp=85074340969&partnerID=8YFLogxK
U2 - 10.1002/pmic.201900174
DO - 10.1002/pmic.201900174
M3 - Article
C2 - 31576646
AN - SCOPUS:85074340969
SN - 1615-9853
VL - 19
SP - 1
EP - 12
JO - Proteomics
JF - Proteomics
IS - 21-22
M1 - 1900174
ER -